



[www.genfit.com](http://www.genfit.com)

## GENFIT TO PARTICIPATE AT THE BIO INTERNATIONAL CONVENTION IN BOSTON ON JUNE 18-21, 2012

**Lille (France), Cambridge (Massachusetts, United States), June 12, 2012** – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces its participation at the BIO International Convention taking place at the Boston Convention & Exhibition Center (BCEC) on June 18-21, 2012.

The BIO International Convention is an internationally-renowned biotechnology conference and represents a unique opportunity to meet industrials, scientific experts, and investors, and to create new partnerships. The Company will be represented at this meeting by Jean-François Mouney, co-founder and CEO, and Dr. Dean W. Hum, CSO.

« *The positive results obtained since the beginning of the year for GFT505, our leading drug candidate, as well as the recent progress on our other proprietary research programs, have generated a strong interest within the pharmaceutical industry. We thus hope that the numerous meetings planned at BIO will yield productive discussions.* » declared Dr. Karine Bertrand, EVP Corporate Business Development.

### **About GENFIT:**

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

### **Contacts:**

#### **GENFIT**

Jean-François Mouney – CEO & Chairman of the Management Board  
Ph. +333 2016 4000

#### **MILESTONES – Press Relations**

Bruno Arabian  
Ph. +33 1 7544 8740 / +336 8788 4726 – [barabian@milestones.fr](mailto:barabian@milestones.fr)